Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors



Rating:

Share or cite this content

Citations should be made in the following way:
O. Fesenko (Moscow, Russian Federation). The practice of empiric antibiotic therapy in patients with coronavirus disease 2019 (COVID-19).. 818

Member's Comments

No comment yet.

Related content which might interest you: Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Correlation between eradication of infecting organism on days 3-5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice. Source: International Congress 2017 – COPD management Year: 2017 Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 “Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy” Breathe 2019; 15: 296–304. Source: Breathe, 15 (4) e152; 10.1183/20734735.5258-2019 Year: 2019 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006 Should we change our antibiotic strategy in AECOPD or CAP+COPD patients? Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients Year: 2015 Antibiotic resistance and clinical outcomes: the CAPNETZ experience Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease Source: International Congress 2019 – M-health/e-health I Year: 2019 Developing outcome-based guidelines in CAP and AECB Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005